aidsmap news story
An experimental combination pill containing islatravir and ulonivirine shows promise as a weekly oral treatment option, according to study results presented at AIDS 2026.
Merck’s islatravir is the first nucleoside reverse transcriptase translocation inhibitor, which interferes with the HIV enzyme in a different way than familiar nucleoside/nucleotide reverse transcriptase inhibitors. A once-daily pill combining islatravir and doravirine, sold as Idvynso, was approved in the US in April.
Ulonivirine (formerly known as MK-8507) is a next-generation non-nucleoside reverse transcriptase inhibitor with activity against HIV strains that have developed resistance to older drugs in its class.
Read the full news story here.
View all aidsmap reports from AIDS 2026
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.